The basis of this application arises from new data suggesting the hypothesis that cells at intermediate oxygen concentrations (centered around approximately 1%) dominate the therapeutic response and biology of tumors. Our hypothesis originated from in vivo studies utilizing a quantitative method for determining tissue hypoxia. This method, developed in our laboratory, measures binding of the 2-nitroimidazole hypoxia marker EF5 (2-(2-nitro-1H-imidazol-1-yl)-N- (2,2,3,3,3-pentafluoropropyl)acetamide). The bound EF5 adducts are measured using fluorescent monoclonal antibodies and a fluorescence scale calibrated to biological measures of actual cellular pO2. Use of this method predicts the radiation response in individual rat tumors of two types studied to date (9L glioma and Morris 7777 hepatoma). There have been two models proposed for the production of tumor hypoxia: in the first, blood flow is in a steady state leading to diffusion limited hypoxia whereas in the second, blood flow cycles on and off leading to perfusion limited hypoxia. Which of these models is most relevant, in either rodent or human tumors, remains an important unresolved question. Despite having many biological and therapeutic ramifications, it has previously been addressed solely by indirect methods. Since the two models of hypoxia are predicted to form different patterns of hypoxia with respect to the tumor vasculature, we propose a direct investigation of this question by detailed 3-dimensional image analysis, using subcutaneous and orthotopic human xenograft tumors in nude rats. To support the in vivo image analysis studies, quantitative assessments of the biochemical and molecular consequences of steady state vs. cycling hypoxia will be made in vitro. These studies will emphasize those molecular markers known to be modified by the tumor microenvironment and presently under consideration as clinical prognostic markers (e.g. HIF-1alpha, Carbonic Anhydrase IX, Glut-1 and VEGF). Studies in humans continue to support the importance of hypoxia in limiting treatment response - thus new sensitization approaches are required. A new perfluorochemical emulsion (PFC) made by the Sonus Company (Seattle) will be employed to determine whether hypoxic tumor cells (both intermediate and severe hypoxia) can be targeted therapeutically. This emulsion (DDFP) has the remarkable property of forming stable, sub-micron sized gas bubbles above 28 degrees. The DDFP bubbles, like former liquid PFC emulsions, serve as high-capacity oxygen carriers but, unlike all previous formulations, do so at much lower concentrations. DDFP may thus be the first PFC emulsion practical and safe for use in multifraction clinical regimens.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
2R01CA074071-05A1
Application #
6612202
Study Section
Radiation Study Section (RAD)
Program Officer
Stone, Helen B
Project Start
1998-02-05
Project End
2007-03-31
Budget Start
2003-04-01
Budget End
2004-03-31
Support Year
5
Fiscal Year
2003
Total Cost
$282,537
Indirect Cost
Name
University of Pennsylvania
Department
Radiation-Diagnostic/Oncology
Type
Schools of Medicine
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Evans, Sydney M; Jenkins, Kevin W; Jenkins, W Timothy et al. (2008) Imaging and analytical methods as applied to the evaluation of vasculature and hypoxia in human brain tumors. Radiat Res 170:677-90
Koch, Cameron J (2008) Importance of antibody concentration in the assessment of cellular hypoxia by flow cytometry: EF5 and pimonidazole. Radiat Res 169:677-88
Lee, Deanna C; Adams, Christopher S; Albert, Todd J et al. (2007) In situ oxygen utilization in the rat intervertebral disc. J Anat 210:294-303
Tuttle, Stephen W; Maity, Amit; Oprysko, Patricia R et al. (2007) Detection of reactive oxygen species via endogenous oxidative pentose phosphate cycle activity in response to oxygen concentration: implications for the mechanism of HIF-1alpha stabilization under moderate hypoxia. J Biol Chem 282:36790-6
Pore, Nabendu; Gupta, Anjali K; Cerniglia, George J et al. (2006) Nelfinavir down-regulates hypoxia-inducible factor 1alpha and VEGF expression and increases tumor oxygenation: implications for radiotherapy. Cancer Res 66:9252-9
Evans, Sydney M; Judy, Kevin D; Dunphy, Isolde et al. (2004) Comparative measurements of hypoxia in human brain tumors using needle electrodes and EF5 binding. Cancer Res 64:1886-92
Busch, Theresa M; Wileyto, E Paul; Evans, Sydney M et al. (2003) Quantitative spatial analysis of hypoxia and vascular perfusion in tumor sections. Adv Exp Med Biol 510:37-43
Nadal-Desbarats, L; Poptani, H; Oprysko, P et al. (2002) Effects of hyperglycemia on oxygenation, radiosensitivity and bioenergetic status of subcutaneous RIF-1 tumors. Int J Oncol 21:103-10
Clyman, Ronald I; Seidner, Steven R; Kajino, Hiroki et al. (2002) VEGF regulates remodeling during permanent anatomic closure of the ductus arteriosus. Am J Physiol Regul Integr Comp Physiol 282:R199-206
Koch, Cameron J; Oprysko, Patricia R; Shuman, A Lee et al. (2002) Radiosensitization of hypoxic tumor cells by dodecafluoropentane: a gas-phase perfluorochemical emulsion. Cancer Res 62:3626-9

Showing the most recent 10 out of 17 publications